KALA BIO Settles Approximately $10.6 million of Debt
KALA BIO (NASDAQ:KALA) announced it has completed a loan settlement with Oxford Finance, resolving approximately $10.6 million of debt as of December 26, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
KALA BIO (NASDAQ:KALA) announced it has completed a loan settlement with Oxford Finance, resolving approximately $10.6 million of debt as of December 26, 2025. The company made a $2.0 million payment required under a November 25, 2025 Loan Settlement Agreement, which fully satisfied obligations under the Settlement Agreement and the underlying May 4, 2021 Loan Agreement.
Management said the settlement removes a material overhang and increases strategic flexibility. Separately, on December 30, 2025, the board approved inducement grants totaling 400,000 common shares to four new employees.
Positive
- Settled approximately $10.6 million of debt as of December 26, 2025
- Completed required $2.0 million payment to Oxford Finance, discharging loan obligations
Negative
- Granted 400,000 common shares as inducements on December 30, 2025, which may dilute existing shareholders
Details
News Market Reaction – KALA
On Jan 6, the first trading day after this news, KALA closed 6.90% above the previous close. That session’s volume was 2.9x the stock’s average daily volume.
Data tracked by StockTitan Argus for the Jan 6 session.
Key Figures
- Debt settled
- approximately $10.6 million
- Oxford debt obligations as of December 26, 2025
- Settlement payment
- $2 million
- Obligation to Oxford under Loan Settlement Agreement
- Payment completed
- $2 million
- Recent payment satisfying Settlement and Loan Agreements
- Inducement shares
- 400,000 shares
- Common stock awards as a material inducement to employment
Historical Context
-
Registered direct equity financing to raise $10M mainly for debt repayment.
-
Announcement of at-the-market $10M registered direct equity deal.
-
$6M securities purchase agreement and appointment of David Lazar as CEO.
-
CHASE Phase 2b trial for KPI-012 failed endpoints; program and platform discontinued.
-
Presentation at H.C. Wainwright conference with investor meetings scheduled.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
loan settlement agreement financial
events of default financial
loan and security agreement financial
common stock awards financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
ARLINGTON, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), (“KALA” or the “Company”) today announced the successful completion of its loan settlement with Oxford Finance, LLC (“Oxford”), marking a transformational milestone for the Company. The completion of the settlement resolves critical debt obligations.
As previously disclosed in the Company’s Current Report on Form 8-K filed on November 25, 2025, KALA and its subsidiary Combangio, Inc., entered into a Loan Settlement Agreement with Oxford pursuant to which the Company owed Oxford
Recently, KALA completed its
“The successful completion of the Oxford settlement represents a watershed moment for KALA BIO,” said David E. Lazar, Chief Executive Officer and Chairman of the Board. “By settling the Company’s debt obligations and increasing stockholders’ equity, we have removed a substantial overhang that was constraining the Company’s strategic flexibility. We are confident in our path forward.”
Also, as of December 30, 2025, the Company, with the Compensation Committee of KALA’s Board of Directors’ approval, granted common stock awards as a material inducement to employment to four individuals hired by KALA, which common stock awards relate to, in the aggregate, 400,000 shares of common stock.
KALA Contact
David Lazar
Chief Executive Officer and Chairman of the Board
david@activistinvestingllc.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.